（原标题：一脉阳光积极回应投资者关切：长期看好公司发展前景 回购+增持彰显坚定信心） 一脉阳光随后公布，有意不时于公开市场进一步购回H股，购回金额累计不超过2亿港元。据悉，本次 回购决定是基于其对集团近期在区域性医学影像共享中心、医学影像数据服务等业务领域所取得的阶段 性发展成果，以及集团在打造"数据+AI/算法+应用场景"的智慧医学影像全产业链领域所展现的专业能 力及研发技术的高度肯定。回购计划的实施不仅有利于稳定股价及提升股东回报，也彰显了一脉阳光对 自身股价以及公司未来长期发展的坚定信心。 一脉阳光同时还宣布，基于对公司整体发展前景及增长潜力的信心，为促进公司持续、稳定、健康发 展，维护广大公众投资者利益，公司董事长、执行董事兼行政总裁陈朝阳2025年12月8日在公开市场上 按每股10.10港元的平均价格以总代价600,950港元购入59,500股公司H股，占公司已发行股份总数的约 0.01%。增持股份后，其持股比例升至14.48%。 国内医学影像龙头企业一脉阳光(2522.HK)昨日连发三则公告，今日盘前公司高管再度进行交流回复， 积极回应投资者关切。 对于近期股价波动，一脉阳光公开回应称：公司经营一 ...

Core Viewpoint - The stock of Yipai Yangguang (2522.HK) has experienced a significant increase, rising over 11% in the last three trading days, driven by insider buying and positive developments in its business sectors [1] Group 1: Stock Performance - Yipai Yangguang's stock opened high today, reaching a peak increase of 4.4% to HKD 16.62 [1] - The stock has seen a cumulative rise of over 11% over the past three trading days [1] Group 2: Insider Buying - Company directors, including the Chairman and CEO Chen Chaoyang, purchased a total of 96,500 shares of the company's H-shares using personal funds on November 3 and 4, 2025 [1] - The decision for this increase in shareholding is based on the directors' confidence in the company's recent achievements in regional medical imaging sharing centers and data services [1] Group 3: Business Development and Strategic Alignment - The company has demonstrated strong capabilities in the "data + AI/algorithm + application scenario" full industry chain of smart medical imaging, which has been positively recognized [1] - The company's strategic layout in innovation aligns well with the State Council's implementation opinions on promoting and regulating the application of "AI + healthcare" issued on November 4, 2025 [1] - Directors believe that the current H-share price does not fully reflect the long-term investment value of the company [1]

Core Viewpoint - The company Yipai Yangguang (02522) has seen its stock price increase by approximately 4%, attributed to recent insider purchases and positive developments in its business areas related to medical imaging and AI technology [1] Company Summary - Yipai Yangguang's stock rose by 3.96% to HKD 16.55, with a trading volume of HKD 87.4613 million [1] - The company's board members, including the chairman and CEO, purchased a total of approximately 96,500 shares of the company's H-shares using personal funds on November 3 and 4 [1] - The decision for the share buyback was based on the board's confidence in the company's recent achievements in regional medical imaging sharing centers and data services [1] Industry Summary - On November 4, the National Health Commission and other departments released guidelines to promote and standardize the application of "AI + healthcare," aiming for comprehensive coverage of intelligent auxiliary applications in primary care by 2030 [1] - The guidelines emphasize the widespread implementation of AI-assisted diagnosis and clinical decision-making in hospitals above the secondary level, along with the establishment of a robust standardization system for AI applications in healthcare [1]

Core Viewpoint - The company Yipai Yangguang (02522) has seen its stock price increase by approximately 4%, reaching HKD 16.55, with a trading volume of HKD 87.46 million, following the announcement of share purchases by its executives, indicating confidence in the company's recent developments in the medical imaging sector [1] Group 1: Company Actions - The board of Yipai Yangguang has reported that on November 3 and 4, key executives, including the Chairman and CEO Chen Chaoyang, purchased a total of approximately 96,500 shares of the company's H-shares using personal funds [1] - The executives' decision to increase their holdings is based on their recognition of the company's recent achievements in regional medical imaging sharing centers and medical imaging data services [1] Group 2: Industry Developments - On November 4, multiple government departments, including the National Health Commission and the National Development and Reform Commission, released implementation opinions to promote and regulate the application of "Artificial Intelligence + Healthcare" [1] - The document outlines goals for 2030, including the full coverage of intelligent auxiliary applications in primary healthcare, and the widespread implementation of AI technologies in secondary hospitals for medical imaging diagnosis and clinical decision-making [1]

Core Viewpoint - The company, Yipai Yangguang (02522), announced that several directors purchased a total of 96,500 H-shares in the open market, reflecting their confidence in the company's recent developments in medical imaging and AI applications [1] Group 1: Director Purchases - The chairman and CEO, Mr. Chen Chaoyang, along with other executive directors, purchased a total of 96,500 H-shares on November 3 and 4, 2025 [1] - The directors indicated that their decision to increase their holdings was based on the company's recent achievements in regional medical imaging sharing centers and data services [1] Group 2: Strategic Alignment and Confidence - The company's strategic layout in innovative fields aligns well with the State Council's recent implementation opinions on promoting and regulating AI in healthcare, issued on November 4, 2025 [1] - The directors expressed strong confidence in the company's future development prospects, believing that the current H-share price does not fully reflect the long-term investment value of the group [1] Group 3: Compliance and Public Holdings - The company maintains sufficient public shareholding as per the regulations of the Hong Kong Stock Exchange, even after the recent share purchases by the directors [1]

Core Viewpoint - The company, Yipai Yangguang (02522), announced that its directors purchased a total of 96,500 H-shares in the open market, reflecting their confidence in the company's recent developments in medical imaging and AI applications [1] Group 1: Director Purchases - The chairman and CEO, Mr. Chen Chaoyang, along with other executive directors, purchased a total of 96,500 H-shares on November 3 and 4, 2025 [1] - The directors believe that the current H-share price does not fully reflect the company's long-term investment value [1] Group 2: Business Development - The directors' decision to increase their holdings is based on the company's recent achievements in regional medical imaging sharing centers and data services [1] - The company's strategic alignment with the State Council's implementation opinions on promoting AI in healthcare, issued on November 4, 2025, enhances their confidence in future growth [1] Group 3: Market Position - The company maintains sufficient public float in compliance with the Hong Kong Stock Exchange's listing rules, even after the recent share purchases [1]